Globus Medical, Medtronic plc, Hill Rom Holdings, Haemonetics Corporation, Becton Dickinson and Company, Baxter International, Second Sight Medical Products, and Establishment Labs Holdings" name="Description" /> Globus Medical, Medtronic plc, Hill Rom Holdings, Haemonetics Corporation, Becton Dickinson and Company, Baxter International, Second Sight Medical Products, and Establishment Labs Holdings" /> Globus Medical, Medtronic plc, Hill Rom Holdings, Haemonetics Corporation, Becton Dickinson and Company, Baxter International, Second Sight Medical Products, and Establishment Labs Holdings" />

The Top 8 Medical Equipment stocks to own in September 2019

Today article will analyze 8 Medical Equipment isntruments to have in your portfolio in September 2019. I will specifically cover the following equities: Globus Medical, Medtronic plc, Hill Rom Holdings, Haemonetics Corporation, Becton Dickinson and Company, Baxter International, Second Sight Medical Products, and Establishment Labs Holdings
Published over a year ago
View all stories for Macroaxis | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Michael Smolkin

This list of potential positions covers USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty

Globus Medical (GMED)

The company has return on total asset (ROA) of 0.0477 % which means that it generated a profit of $0.0477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0421 %, meaning that it created $0.0421 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Mid-Cap' category with a current market capitalization of 6.92 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Globus Medical's market, we take the total number of its shares issued and multiply it by Globus Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Globus Medical retains a regular Real Value of $53.45 per share. The prevalent price of the firm is $53.06. Our model calculates the value of Globus Medical from evaluating the firm fundamentals such as Return On Asset of 0.0477, return on equity of 0.0421, and Current Valuation of 6.93 B as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and exiting overvalued assets since, at some point, asset prices and their ongoing real values will come together.

Medtronic PLC (MDT)

The company has Return on Asset of 0.0423 % which means that on every $100 spent on assets, it made $0.0423 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0817 %, implying that it generated $0.0817 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to 0.05 in 2024. Return On Assets is likely to drop to 0.04 in 2024. Total Current Liabilities is likely to gain to about 10.9 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 109.8 B in 2024The entity currently falls under 'Mega-Cap' category with a total capitalization of 111.14 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medtronic PLC's market, we take the total number of its shares issued and multiply it by Medtronic PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

29.42 Billion

At this time, Medtronic PLC's Short and Long Term Debt Total is comparatively stable compared to the past year.

Hill Rom Holdings (HRC)

The company has Return on Asset of 6.13 % which means that on every $100 spent on assets, it made $6.13 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 13.78 %, implying that it generated $13.78 on every 100 dollars invested. Hill Rom's management efficiency ratios could be used to measure how well Hill Rom manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a total capitalization of 10.37 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hill Rom's market, we take the total number of its shares issued and multiply it by Hill Rom's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Haemonetics (HAE)

The company has Return on Asset of 0.0612 % which means that on every $100 spent on assets, it made $0.0612 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1472 %, implying that it generated $0.1472 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Equity is projected to increase slightly based on the last few years of reporting. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 929.4 M, whereas Other Current Assets are forecasted to decline to about 35.8 M. The entity currently falls under 'Mid-Cap' category with a total capitalization of 4.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Haemonetics's market, we take the total number of its shares issued and multiply it by Haemonetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

924.81 Million

At present, Haemonetics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.

Becton Dickinson And (BDX)

The company has Return on Asset of 0.0312 % which means that on every $100 spent on assets, it made $0.0312 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0513 %, implying that it generated $0.0513 on every 100 dollars invested. Becton Dickinson's management efficiency ratios could be used to measure how well Becton Dickinson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to 0.05 in 2024. Return On Assets is likely to drop to 0.03 in 2024. At this time, Becton Dickinson's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 53.3 B in 2024, whereas Intangible Assets are likely to drop slightly above 603.1 M in 2024. The entity currently falls under 'Large-Cap' category with a total capitalization of 69.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Becton Dickinson's market, we take the total number of its shares issued and multiply it by Becton Dickinson's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Becton Dickinson And shows a prevailing Real Value of $250.43 per share. The current price of the firm is $246.53. Our model approximates the value of Becton Dickinson And from analyzing the firm fundamentals such as return on equity of 0.0513, and Profit Margin of 0.06 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.

Baxter International (BAX)

The company has Return on Asset of 0.0334 % which means that on every $100 spent on assets, it made $0.0334 of profit. This is way below average. Baxter International's management efficiency ratios could be used to measure how well Baxter International manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.33 in 2024, whereas Return On Capital Employed is likely to drop 0.02 in 2024. At this time, Baxter International's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 6.4 B in 2024, whereas Total Assets are likely to drop slightly above 16.2 B in 2024. This firm currently falls under 'Large-Cap' category with a total capitalization of 21.1 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Baxter International's market, we take the total number of its shares issued and multiply it by Baxter International's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

15.08 Billion

At this time, Baxter International's Short and Long Term Debt Total is fairly stable compared to the past year.

Second Sight Medical (EYES)

The company has return on total asset (ROA) of (10.74) % which means that it has lost $10.74 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.02) %, meaning that it created substantial loss on money invested by shareholders. Second Sight's management efficiency ratios could be used to measure how well Second Sight manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Small-Cap' category with a current market capitalization of 163.15 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Second Sight's market, we take the total number of its shares issued and multiply it by Second Sight's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Establishment Labs Holdings (ESTA)

The company has return on total asset (ROA) of (0.1694) % which means that it has lost $0.1694 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.3775) %, meaning that it created substantial loss on money invested by shareholders. Establishment Labs' management efficiency ratios could be used to measure how well Establishment Labs manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 1.3 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Establishment Labs's market, we take the total number of its shares issued and multiply it by Establishment Labs's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Current Medical Equipment Recommendations


How important is Macroaxis's Liquidity

Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Story appears to be empty

Globus Medical (GMED)

The company has return on total asset (ROA) of 0.0477 % which means that it generated a profit of $0.0477 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0421 %, meaning that it created $0.0421 on every $100 dollars invested by stockholders. Globus Medical's management efficiency ratios could be used to measure how well Globus Medical manages its routine affairs as well as how well it operates its assets and liabilities. The entity currently falls under 'Mid-Cap' category with a current market capitalization of 6.92 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Globus Medical's market, we take the total number of its shares issued and multiply it by Globus Medical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Globus Medical retains a regular Real Value of $53.45 per share. The prevalent price of the firm is $53.06. Our model calculates the value of Globus Medical from evaluating the firm fundamentals such as Return On Asset of 0.0477, return on equity of 0.0421, and Current Valuation of 6.93 B as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage purchasing undervalued assets and exiting overvalued assets since, at some point, asset prices and their ongoing real values will come together.

Medtronic PLC (MDT)

The company has Return on Asset of 0.0423 % which means that on every $100 spent on assets, it made $0.0423 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0817 %, implying that it generated $0.0817 on every 100 dollars invested. Medtronic PLC's management efficiency ratios could be used to measure how well Medtronic PLC manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to 0.05 in 2024. Return On Assets is likely to drop to 0.04 in 2024. Total Current Liabilities is likely to gain to about 10.9 B in 2024. Liabilities And Stockholders Equity is likely to gain to about 109.8 B in 2024The entity currently falls under 'Mega-Cap' category with a total capitalization of 111.14 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medtronic PLC's market, we take the total number of its shares issued and multiply it by Medtronic PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

29.42 Billion

At this time, Medtronic PLC's Short and Long Term Debt Total is comparatively stable compared to the past year.

Hill Rom Holdings (HRC)

The company has Return on Asset of 6.13 % which means that on every $100 spent on assets, it made $6.13 of profit. This is considered to be average in the sector. In the same way, it shows a return on shareholders' equity (ROE) of 13.78 %, implying that it generated $13.78 on every 100 dollars invested. Hill Rom's management efficiency ratios could be used to measure how well Hill Rom manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Large-Cap' category with a total capitalization of 10.37 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hill Rom's market, we take the total number of its shares issued and multiply it by Hill Rom's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Haemonetics (HAE)

The company has Return on Asset of 0.0612 % which means that on every $100 spent on assets, it made $0.0612 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1472 %, implying that it generated $0.1472 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Equity is projected to increase slightly based on the last few years of reporting. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 929.4 M, whereas Other Current Assets are forecasted to decline to about 35.8 M. The entity currently falls under 'Mid-Cap' category with a total capitalization of 4.15 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Haemonetics's market, we take the total number of its shares issued and multiply it by Haemonetics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

924.81 Million

At present, Haemonetics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting.

Becton Dickinson And (BDX)

The company has Return on Asset of 0.0312 % which means that on every $100 spent on assets, it made $0.0312 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0513 %, implying that it generated $0.0513 on every 100 dollars invested. Becton Dickinson's management efficiency ratios could be used to measure how well Becton Dickinson manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to 0.05 in 2024. Return On Assets is likely to drop to 0.03 in 2024. At this time, Becton Dickinson's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 53.3 B in 2024, whereas Intangible Assets are likely to drop slightly above 603.1 M in 2024. The entity currently falls under 'Large-Cap' category with a total capitalization of 69.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Becton Dickinson's market, we take the total number of its shares issued and multiply it by Becton Dickinson's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Becton Dickinson And shows a prevailing Real Value of $250.43 per share. The current price of the firm is $246.53. Our model approximates the value of Becton Dickinson And from analyzing the firm fundamentals such as return on equity of 0.0513, and Profit Margin of 0.06 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.

Baxter International (BAX)

The company has Return on Asset of 0.0334 % which means that on every $100 spent on assets, it made $0.0334 of profit. This is way below average. Baxter International's management efficiency ratios could be used to measure how well Baxter International manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 0.33 in 2024, whereas Return On Capital Employed is likely to drop 0.02 in 2024. At this time, Baxter International's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 6.4 B in 2024, whereas Total Assets are likely to drop slightly above 16.2 B in 2024. This firm currently falls under 'Large-Cap' category with a total capitalization of 21.1 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Baxter International's market, we take the total number of its shares issued and multiply it by Baxter International's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Short Long Term Debt Total

15.08 Billion

At this time, Baxter International's Short and Long Term Debt Total is fairly stable compared to the past year.

Second Sight Medical (EYES)

The company has return on total asset (ROA) of (10.74) % which means that it has lost $10.74 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.02) %, meaning that it created substantial loss on money invested by shareholders. Second Sight's management efficiency ratios could be used to measure how well Second Sight manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Small-Cap' category with a current market capitalization of 163.15 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Second Sight's market, we take the total number of its shares issued and multiply it by Second Sight's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Establishment Labs Holdings (ESTA)

The company has return on total asset (ROA) of (0.1694) % which means that it has lost $0.1694 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.3775) %, meaning that it created substantial loss on money invested by shareholders. Establishment Labs' management efficiency ratios could be used to measure how well Establishment Labs manages its routine affairs as well as how well it operates its assets and liabilities. The firm currently falls under 'Mid-Cap' category with a current market capitalization of 1.3 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Establishment Labs's market, we take the total number of its shares issued and multiply it by Establishment Labs's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Current Medical Equipment Recommendations

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Did you try this?

Run Portfolio Analyzer Now

   

Portfolio Analyzer

Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
All  Next Launch Module
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Consideration for investing

Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Fundamental Analysis
View fundamental data based on most recent published financial statements